British American Tobacco Industries p.l.c. (BTI) vs Definium Therapeutics (DFTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed British American Tobacco Industries p.l.c. (BTI) over the past year, gaining 193.1% versus a gain of 3.7%. Over five years, BTI leads with a +49.3% price change compared with -0.5% for DFTX. British American Tobacco Industries p.l.c. is the larger company by market cap ($115.94 billion vs $4.71 billion), about 24.6 times the size.
British American Tobacco Industries p.l.c. pays a dividend yielding 4.55%, while Definium Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BTI | DFTX |
|---|---|---|
| Share price | $53.90 | $35.09 |
| Market cap | $115.94B | $4.71B |
| 1-day change | +1.68% | -1.49% |
| YTD return | -4.80% | +162.06% |
| 1-year return | +3.69% | +193.15% |
| 5-year return | +49.31% | -0.45% |
| P/E ratio (TTM) | 13.82 | — |
| Forward P/E | 10.29 | — |
| EPS (TTM) | $3.90 | $-3.43 |
| Dividend yield | 4.55% | 0.00% |
| Annual dividend | $2.45 | $0.00 |
| Net income (latest FY) | — | $-183.79M |
| 52-week high | $67.30 | $49.70 |
| 52-week low | $49.88 | $10.47 |
| Distance from 52-week high | -19.91% | -29.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +30.67% | +104.19% |
| Average volume | 4.58M | 2.14M |
| Shares outstanding | 2.15B | 134.37M |
| Employees | 47,797 | 105 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- British American Tobacco Industries p.l.c. is about 24.6 times larger than Definium Therapeutics by market value ($115.94B vs $4.71B).
- DFTX has outperformed BTI by 189.5 percentage points over the past year.
- British American Tobacco Industries p.l.c. offers a meaningfully higher dividend yield (4.55% vs 0.00%).
About British American Tobacco Industries p.l.c.
BTI stock →British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the United States, Europe, Latin America, Canada, the Asia-Pacific, the Middle East, Central Asia, Caucasus, and Africa.
Health Care · Medicinal Chemicals and Botanical Products · 47,797 employees
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
BTI vs DFTX FAQ
Which is bigger, British American Tobacco Industries p.l.c. or Definium Therapeutics?
British American Tobacco Industries p.l.c. (BTI) is larger, with a market capitalization of $115.94B compared with $4.71B for Definium Therapeutics (DFTX).
Which stock has performed better over the past year, BTI or DFTX?
DFTX returned +193.15% over the past 12 months, compared with +3.69% for BTI (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, British American Tobacco Industries p.l.c. or Definium Therapeutics?
British American Tobacco Industries p.l.c. pays a dividend yielding 4.55%, while Definium Therapeutics does not currently pay a regular dividend.
Are British American Tobacco Industries p.l.c. and Definium Therapeutics in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.